Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?

首页> 外文期刊>Nature clinical practice. Oncology >Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?

【24h】

Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?

机译：在MP或低强度SCT中添加沙利度胺是否可以改善老年多发性骨髓瘤患者的生存率？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The combination chemotherapy regimen of melphalan and prednisone is widely accepted as the standard of care for elderly patients with multiple myeloma; however, new treatments are needed to improve survival.To assess whether the addition of thalidomide to-melphalan plus prednisone or reduced-intensity stem-cell transplantation improve survival in elderly patients with multiple myeloma.

机译：美法仑和泼尼松的联合化疗方案已被广泛接受为老年多发性骨髓瘤患者的治疗标准。然而，需要新的治疗方法来提高生存率。为了评估向多法骨髓中加入沙利度胺和泼尼松或降低强度的干细胞移植能否改善老年多发性骨髓瘤患者的生存率。

著录项

来源
《Nature clinical practice. Oncology》 |2008年第5期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
multiple myeloma and other plasma cell neoplasms; survival aspects; Elderly; 沙立度胺; 泼尼松;

机译：multiple myeloma and other plasma cell neoplasms;survival aspects;Elderly;沙立度胺;泼尼松;

相似文献

外文文献
中文文献
专利

1. Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients? [J] . Nature clinical practice. Oncology . 2008,第5期

机译：在MP或低强度SCT中添加沙利度胺是否可以改善老年多发性骨髓瘤患者的生存率？
2. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. [J] . Antonio Palumbo, Sara Bringhen, Alessandra Larocca, Journal of Clinical Oncology . 2014,第7期

机译：Bortezomib-Melphalan-prednisone-renalomide随后与Bortezomib-Melphalan-Prednisone进行硼替佐米胺维持，用于初始治疗多发性骨髓瘤：更新后续和提高存活。
3. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. [J] . Antonio Palumbo, Sara Bringhen, Alessandra Larocca, Journal of Clinical Oncology . 2014,第7期

机译：Bortezomib-Melphalan-prednisone-renalomide随后与Bortezomib-Melphalan-Prednisone进行硼替佐米胺维持，用于初始治疗多发性骨髓瘤：更新后续和提高存活。
4. Multiple Arterial Grafts Improve Late Survival of Multivessel Disease Patients Undergoing Cabg [C] . Locker C., Daly R.C., Dearani J.A., International Congress on Coronary Artery Disease. . 2013

机译：多个动脉移植物改善了患者患者发布的多血糖疾病患者的晚期存活
5. CD28-Mediated Pro-Survival Signaling: A Novel Therapeutic Target for the Treatment of Multiple Myeloma [D] . Murray, Megan Elizabeth 2015

机译：CD28介导的生存前信号：一种新型的治疗靶点治疗多发性骨髓瘤。
6. Clinical Trials and Observations: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities [O] . Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, -1

机译：临床试验和观察：总疗法2的沙利度胺有助于改善患有中期细胞遗传学异常的骨髓瘤患者的完全缓解持续时间和存活率
7. Retraction Note: First-line thalidomide–dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma [O] . A Abdelkefi, L Torjman, N Ben Romdhane, 2009

机译：收缩注意：一线三度胺类 - 地塞米松治疗患者在患有症状多发性骨髓瘤中的幼体患者（<61岁）

Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?

摘要

著录项

相似文献

相关主题

期刊订阅